We tested for Mycoplasma genitalium in 157 HIV-infected men. Urogenital and rectal prevalence were 10.8% and 6.4%. Macrolide resistance mutations were detected in 70.6% and 80% of urogenital and rectal samples, and fluoroquinolone resistance mutations in 26.7% and 40%, respectively.
Mycoplasma genitalium is a sexually transmitted bacterial pathogen that causes up to 20% of nongonococcal urethritis and has been detected in 12% of men who have sex with men (MSM) with proctitis [1, 2] . Many M. genitalium infections are asymptomatic, and surveillance is limited by the lack of a Food and Drug Administration (FDA)-approved diagnostic test. The US Centers for Disease Control and Prevention (CDC) recommends single-dose azithromycin (1 g) as first-line M. genitalium therapy and moxifloxacin (400 mg/d for 7, 10, or 14 days) as second-line therapy for cases of suspected treatment failure [1] . Efficacy of M. genitalium treatment is threatened by rapid emergence of antimicrobial resistance [3] .
The most common mutations that confer macrolide resistance in M. genitalium are A2071G (Escherichia coli numbering 2058) and A2072G (E. coli numbering 2059) in the 23S ribosomal RNA (rRNA) gene, known as macrolide resistancemediating mutations (MRMMs). Fluoroquinolone resistance in M. genitalium can be mediated by mutations in quinolone resistance-determining regions (QRDRs) of topoisomerase IV and DNA gyrase genes (mostly parC and gyrA, but also parE and gyrB). Data linking QRDR mutations to treatment failures are limited, compared with the proven association with MRMMs [4] .
MSM with human immunodeficiency virus (HIV) infection have elevated rates of M. genitalium infection compared with HIV-uninfected MSM but little is known about infection prevalence and antimicrobial resistance patterns in HIV-infected MSM in the United States [2] . Because surveillance data inform M. genitalium screening and treatment recommendations, we evaluated the prevalence of M. genitalium infection and antimicrobial resistance among HIV-infected MSM in Alabama.
METHODS
This is a substudy of a sexually transmitted infection (STI) study that enrolled HIV-infected MSM from a HIV primary care clinic in Birmingham, Alabama. MSM in active care were eligible if they were ≥19 years old, reported receptive anal intercourse in the past 30 days, and had no exposure to antibiotics in the past 30 days (except for trimethoprim-sulfamethoxazole). Participants were asked about STI symptoms (dysuria, penile/ rectal discharge, proctitis, testicular pain/swelling), STI history, number of sex partners, and condom use in the past 30 days. CD4 cell count and HIV load were abstracted from the medical record for the date closest to and within 6 months of the visit. Nucleic acid amplification testing had been performed for chlamydia and gonorrhea at urogenital and rectal sites. For this substudy, archived self-collected rectal swab and first-catch urine samples were tested for M. genitalium and the presence of M. genitalium-associated macrolide and fluoroquinolone resistance mutations. The study was approved by the University of Alabama at Birmingham (UAB) Institutional Review Board.
Statistical Analyses
M. genitalium infection prevalence was calculated as the number of real-time polymerase chain reaction (PCR)-positive infections per number of PCR tests. For categorical variables, χ 2 or Fisher exact tests were used to compute P values. Because continuous variables were nonnormally distributed, a nonparametric 1-way analysis of variance was used, and P values were calculated using the Kruskal-Wallis test. Significance was set at P < .05, and analyses were performed with SAS software (version 9.4).
Detection of Mycoplasma genitalium and Macrolide Resistance
A modified real-time PCR assay targeting the 23S rRNA gene was used to detect M. genitalium directly from clinical specimens and simultaneously identify mutations known to confer macrolide resistance [5] . 
Nested Polymerase Chain Reaction
Four nested traditional PCRs were used to detect mutations in gyrA, gyrB, parC, and parE genes using published and newly designed primers [4] . PCR products were sequenced by the UAB Heflin Center for Genomic Science and analyzed with CLC Main Workbench 7.8.1.
RESULTS

Demographic and Clinical Characteristics
The study included 157 HIV-infected MSM enrolled between December 2014 and November 2016. Their median age was 34 years (interquartile range, 29-46 years), 42.7% reported >1 sex partner in the past month, 96% had sex with men only, and 75% used condoms inconsistently or not at all. The majority of subjects (61%) were practicing receptive and insertive anal intercourse, and 77% had a history of STI. The median CD4 cell count was in the normal range (565 cells/mL; interquartile range 415-787 cells/ mL), and 85.3% of subjects had an HIV load <200 copies/mL.
Mycoplasma genitalium Infection Prevalence
The prevalence of M. genitalium infection was 17.2% (27 of 157): 10.8% at the urogenital and 6.4% at the rectal site. Two in 3 men (66%; 104 of 157) were African American, but neither race nor CD4 cell count <350/μL was associated with M. genitalium infection. The bacterial load ranged from 2 to 32 700 genome copies (GCs)/µL, with a median of 72 GCs/µL. There was no significant different in organism load by site (49.1 GCs/µL for urogenital vs 91.5 GCs/µL for rectal samples; P = .47). Only 11.8% (2 of 17) with urogenital infection and 20% (2 of 10) with rectal infection reported STI symptoms. The prevalence of urogenital and rectal chlamydia in study subjects was 2.5% and 14.6%, respectively, and the prevalence of urogenital and rectal gonorrhea, 0% and 7%.
Resistance Testing
MRMMs were detected in 20 of 27 M. (Figure 1 ).
DISCUSSION
In this study, 1 in 6 HIV-infected MSM in Birmingham, Alabama, had M. genitalium infection at urogenital or rectal sites. Of notable concern, most M. genitalium-positive specimens carried mutations associated with macrolide or fluoroquinolone resistance, and 30% of rectal specimens harbored mutations associated with resistance to both drug classes. This finding has the potential to limit the efficacy of both first-and second-line CDC-recommended therapies for M. genitalium. Some people in the United States may be infected with M. genitalium, for which there is no known effective treatment, and this raises concern about the potential spread of a multidrug resistant pathogen. There has been increasing clinical awareness and public health concern about failure of azithromycin treatment for M. genitalium infection [1] . Azithromycin treatment efficacy fell precipitously from 87% to 40% in 3 randomized controlled trials published between 2009 and 2013 [3] . A 2017 study of a 5-day azithromycin regimen showed no benefit in microbiologic cure rates compared with single-dose therapy [6] . The prevalence of MRMMs among adults with urogenital M. genitalium is as high as 51% in the United States and 52%-72% in Australia [6] [7] [8] . Other treatment options are limited because M. genitalium lacks a cell wall (thus inherent resistance to β-lactams), and cure rates with doxycycline are low (31%-45%) [3] .
Moxifloxacin has favorable potency against M. genitalium compared with other available quinolones, but a 2017 meta-analysis demonstrated a decrease in moxifloxacin efficacy for M. genitalium infection from 100% to 89% since 2010 [9] . Reported global frequencies of QRDR mutations in urogenital M. genitalium infection include 18.6% in the Asia-Pacific region, 15% in Australia, and 6% in Russia and France [3, [10] [11] [12] .
Our study fills an important knowledge gap, because to our knowledge there are no published reports on the prevalence of fluoroquinolone resistance in M. genitalium strains in the United States, and studies focusing on rectal M. genitalium infections in HIV-infected MSM are sparse. Other strengths of our study include use of a novel, sensitive real-time PCR that can simultaneously detect M. genitalium and macrolide resistance mutations on clinical samples.
One limitation of our study is the sample size. In addition, the presence of mutations associated with quinolone resistance may not necessarily correlate with microbiologic and/or clinical failure. Given the sensitivity of PCR and low M. genitalium load noted in some samples, some infections detected may have been clinically insignificant. More studies of M. genitalium are needed to determine the natural history of infection and whether the novel mutations noted in this study are associated with treatment failure.
Surveillance for M. genitalium and drug resistance in the United States is warranted, but lack of a FDA-approved testing to detect infection and resistance is a significant barrier. Some reference laboratories offer in-house M. genitalium PCR assays. Because 85% of M. genitalium-infected MSM in our study were asymptomatic, a policy of routine screening at exposure sites among high-risk MSM may be reasonable but not feasible until testing is more readily available and effective treatment options defined.
In conclusion, novel diagnostic methods facilitated the diagnosis of multidrug-resistant M. genitalium infection, which was highly prevalent in rectal and urogenital sites among HIV-infected MSM in Alabama. Studies of new M. genitalium treatment options should be prioritized, given the rapid development of antimicrobial resistance. Figure 1 . Proportion of Mycoplasma genitalium samples with macrolide and/or fluoroquinolone resistance mutations by site (n = 27); samples were obtained from human immunodeficiency virus-infected men who have sex with men. Abbreviations: MRMMs, macrolide resistance-mediating mutations; QRDR, quinolone resistance-determining region.
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